The prescription drug trend is an important metric

Size: px
Start display at page:

Download "The prescription drug trend is an important metric"

Transcription

1 Generational Impact on Prescription Drug Trend: Part 1 Drug Trends Anna A. Theodorou, RPh, MBA John A. Szychowski, AAS, BS Julie Slezak, MS Steven M. Fox, CPA CVS Caremark The prescription drug trend is an important metric that is affected by drug mix, price, and utilization. The single greatest influence on drug mix and utilization is member age demographics. Because the age of a given population is not something that can be changed to improve the trend, it is important to understand the utilization patterns across age groups. Each generation has an impact on trend because of differing disease prevalences, underlying health, and drug mix. Attitudes toward health, the healthcare industry, and advertising also can affect how and which prescription medications are utilized. The overall drug trend can be broken down by each generation s contribution to the overall trend within our population. There are more people over the age of 83 years than ever before. In addition, by size alone, the most influential peer group of our time is the Baby Boomers, the generation born after World War II through Because older members use more medications, the greater the number of older members, the greater the drug trend will be. Because older members tend to use more prescription drugs than younger members, plans that include a greater concentration of older members generally experience higher levels of drug spending and increases in year-over-year utilization trends. Conversely, a greater number of younger members will result in a lower drug trend. Our population consists of 6 generations. (See the Sidebar for more details.) From the oldest to the youngest, they are as follows: GI generation (born ). Silent generation (born ). Baby Boomer generation (born ). Generation X (born ). Generation Y (born ). Generation Z (born 1991-present). Sidebar. Generations (Birth Years) GI ( ) Assertive and self-reliant Strong civic responsibility Limited access to medications Silent ( ) Willing to compromise, conservative Limited access to medications growing up Physician-centric Baby Boomer ( ) Activist and idealistic More prescription medications available and utilized Individual or patient-centric Generation X ( ) Sophisticated at an early age Early exposure to and use of prescription drugs Individual or patient-centric Generation Y ( ) Usually children of Baby Boomers and people of early Generation X Greater exposure to and use of medications Childhood obesity and chronic disease Generation Z (1991-present) Greater exposure to and use of medications Childhood obesity and chronic disease Source: CVS Caremark Generational Trend Cohort, by GPI-4, YTD December 2008, CVS Caremark Industry Analytics, May VOL. 1, NO. 2 The American Journal of Pharmacy Benefits 111

2 n Theodorou Szychowski Slezak Fox This 2-part article provides an overview of the generational impact on trend among the utilizing members in CVS Caremark s reportable database. Part 1 focuses on important therapeutic classes for all generations. METHODS This was a retrospective study of million prescription claims in a computerized database. The study population was 25.9 million members across a multitude of funded benefit prescription plans administered by CVS Caremark. The plan sponsors included Medicaid, national and local employers, health plans, managed care organizations, insurance companies, unions, and government agencies located throughout the United States with prescription claims for all months between January 1, 2007, and December 31, The generational trend was categorized by age bands: 83 and older, 63 to 82 years, 44 to 62 years, 30 to 43 years, 18 to 29 years, and 17 years and younger. The utilization trend was based on average days supply and gross cost (which includes both plan sponsor and member contributions), and is reported on a per member per month (PMPM) basis. Medicare Part D plans were excluded. Note that the trend includes member contribution (gross trend) and specialty drugs. The plan sponsors had average eligibility changes limited to within ±15% period over period. OVERALL GENERATIONAL TRENDS The calendar year 2008 gross PMPM overall trend, excluding Medicare, was 3.7% and the utilization trend was 0.6% (Table 1). The lowest trend was 2.1% in Generation Z, which represented 26% of the members. Not surprisingly, the highest trend was 14.9% in the GI generation, which includes members age 83 years and older. It is interesting to note that the GI generation had the fewest available medications in their youth and have a high opinion of their physicians and other healthcare providers. Though the overall gross PMPM trend was high at 6% in the 18- to 29-year-olds, Generation Y represented only 14% of the membership and 6% of the cost. The Baby Boomers overall gross trend was 3.1%; this group represented 30% of the trend cohort membership. The study did not include Medicare Part D participants; however, the highest utilization trend was 13.7% in the GI generation, which represented 2% of the membership. The Silent generation comprised 9% of the members in the analysis and had a utilization trend of 2.1% and a gross PMPM trend of 4.7%. More than 45% of the overall gross cost in 2008 was for Baby Boomers medications. The Silent generation was responsible for 24% of the overall gross cost in The gross cost and trend of each generation are affected by the type and quantity of prescription medications utilized. Younger members use fewer chronic medications (eg, statins) and more acute medications (eg, antibiotics). IMPORTANT THERAPEUTIC CLASSES FOR ALL GENERATIONS The top 10 therapeutic classes by gross cost represented more than 32% of the overall spending in The Baby Boomer generation shared many of the same top classes with both Generation X and the Silent generation. Table 2 shows the top therapeutic classes for each of the 6 generations. The most common top 25 therapeutic classes in all generations included proton pump inhibitors, miscellaneous anticonvulsants, sympathomimetics, antidepressants (selective serotonin reuptake inhibitors [SSRIs]), and insulin. All of these classes are common to all generations top 25 class by cost list. Table Drug Trends by Generation Generation (Age Band) Gross PMPM Trend, % Utilization Trend PMPM Days Supply, % Members, % Gross Cost, % GI (83+ y) Silent (63-82 y) Baby Boomer (44-62 y) Generation X (30-43 y) Generation Y (18-29 y) Generation Z (<17 y) All generations PMPM indicates per member per month. Source: CVS Caremark Generational Trend Cohort, by GPI-4, YTD December 2008, CVS Caremark Industry Analytics, May The American Journal of Pharmacy Benefits Summer

3 Generational Impact Table 2. Top Therapeutic Class Rankings by Generation and Gross Cost, 2008 Drug Class All Generations GI Silent Rank Baby Boomer Gen X Gen Y Gen Z Proton pump inhibitors Statins Anticonvulsants, miscellaneous Sympathomimetics Antihypertensive combinations Selective serotonin reuptake inhibitors Serotonin-norepinephrine reuptake inhibitors Insulin Opioid agonists Multiple sclerosis agents Source: CVS Caremark Generational Trend Cohort, by GPI-4, YTD December 2008, CVS Caremark Industry Analytics, May n Proton Pump Inhibitors Proton pump inhibitors were the top-ranked class for the GI generation, Baby Boomers, and Generation X; they were ranked 2nd for the Silent generation and 14th for Generation Z. This class includes Nexium, Prevacid, generic Protonix (pantoprazole), and generic Prilosec (omeprazole). It is interesting to note that the older generations would remember a precursor drug, Tagamet, introduced in 1976 as the first blockbuster ($1 billion in sales) innovative drug. (The Figure, which depicts pharmaceutical industry milestones, provides additional historical context.) 1,2 Generations Y and Z would know H2 blockers such as Zantac and Pepcid as over-the-counter options for heartburn. n Miscellaneous Anticonvulsants The miscellaneous anticonvulsant category was ranked 2nd for Generation X and Generation Y. The market for antiepilepsy drugs is small relative to that of other chronic treatment therapeutic categories. 3 Utilization growth is directly related to the breadth of indications for which many of these products are approved and the extent to which off-label prescribing affects this particular class. Lyrica, for example, is approved for adjunctive use in patients with partial seizures. It also is approved for postherpetic neuralgia, neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia (the first drug to be approved for this indication). 4 A 2006 study found that although 21% of overall medication use is off-label, gabapentin (Pfizer s Neurontin and generics) had the highest proportion of off-label prescriptions for a single product (83%); the off-label prescribing rate for the entire class was 46%. 5 The class was ranked 4th among Baby Boomers and 13th among the Silent generation. n Sympathomimetics Sympathomimetics were ranked among the top 10 classes for all generations. These drugs (eg, Advair, Symbicort) are used by about 6 million asthma patients whose symptoms are not well controlled by other drugs, including inhaled corticosteroids. Two other drugs, Serevent Diskus and Foradil, don t contain an inhaled corticosteroid. n Selective Serotonin Reuptake Inhibitors The SSRI class of antidepressants (eg, Prozac and Zoloft, along with their generics) were ranked among the top 25 classes by all generations, with the highest utilization by Generation X and Generation Y. Results published in July 2008 from a study partially funded by AstraZeneca showed that antidepressants that block the action of the serotonin reuptake mechanism appear to raise the risk of upper gastrointestinal bleeding. The increased risk of bleeding was further augmented by the use of nonsteroidal anti-inflammatory drugs or antiplatelet drugs. 6 This risk may be one reason why these antidepressants were not as commonly used by the Silent and GI generations. n Insulin Insulin was ranked 10th among Baby Boomers and the Silent generation and was ranked 15th and 11th for Generation X and Generation Y, respectively. The class continues to be a contributor to gross trend. A 2007 study by the American Diabetes Association estimated that VOL. 1, NO. 2 The American Journal of Pharmacy Benefits 113

4 n Theodorou Szychowski Slezak Fox approximately 17.5 million Americans have been diagnosed with diabetes, and that the number of people diagnosed with diabetes is growing by roughly 1 million per year. This study estimated that $27 billion is spent on care directly to treat diabetes. 7 Results from a recent study conducted by epidemiologists from the National Institutes of Health and the Centers for Disease Control and Prevention showed that nearly 13% of adults age 20 years or older have diabetes, but that 40% of them have not been diagnosed. Researchers noted that diabetes is especially common in the elderly; nearly one third of those age 65 and older have the disease. An additional 30% of adults have prediabetes, a condition marked by elevated blood sugar that is not yet in the Figure. Time Line of Industry Milestones 1906: The FDA was created. 1938: Food, Drug & Cosmetic Act broadened the FDA s authority, instituted safety regulations. The first CVS/pharmacy opened its doors in PCS Health Systems was founded in 1969, creating the PBM industry. 1997: Ban on DTC drug advertising lifted in the US. 2006: Federal Medicare Part D Rx drug benefit went into effect on January 1. GI Generation Silent Generation Baby Boomer Generation Generation X Generation Y Generation Z Aspirin became available without a prescription in Insulin was introduced in Before insulin, diabetes was generally fatal within a few years of its diagnosis. Synthetic cortisone was invented in Tetracycline was invented in Enovid the first oral contraceptive was introduced in 1960; 1.2 million American women were using the pill just 2 years after Enovid s launch. Tagamet the first effective H2 blocker was introduced in It revolutionized the treatment of duodenal/stomach ulcers and other gastrointestinal disorders. First blockbuster ($1-billion sales) drug. Prozac the first SSRI to be approved was introduced in It revolutionized the treatment of depression and other mental disorders. Zyrtec a second-generation prescription antihistamine was approved for over-the-counter sale in late DTC indicates direct-to-consumer; FDA, US Food and Drug Administration; PBM, pharmacy benefit management; SSRI, selective serotonin reuptake inhibitor. Source: References 1 and The American Journal of Pharmacy Benefits Summer

5 Generational Impact diabetes range. Prediabetes, which causes no symptoms, substantially raises the risk of a heart attack or stroke and of developing type 2 diabetes. Type 2 diabetes accounts for up to 95% of all diabetes cases and virtually all cases of undiagnosed diabetes. The study also found that diabetes is rare in persons age 12 to 19 years, but about 16% of these have prediabetes. 8 IMPACT OF ECONOMY ON THE GENERATIONS The 2008 gross drug trend by generations was influenced by member age demographics, drug mix, and change in the economy in the last half of All generations were affected by the economic downturn; however, joblessness was far higher among younger people than for those later in their careers. For workers under age 29 years, the unemployment rate jumped to more than 11% in December 2008, compared with less than 9% in the same period in 2007, according to Labor Department figures. That is far worse than the overall rate of 7.2%, up from 4.9% in the prior year. The loss of jobs or inability to get employment for Generation Y workers (age years) was far worse, approaching 20%. For workers in their 30s and older, the rate was still under 7% and generally declined as workers got older. 9 At the other end of the spectrum, older workers were not staying on the job longer as the economy worsened. The Social Security Administration (SSA) reported a major surge in early retirement claims. Since the current federal fiscal year began October 1, 2008, claims have been running 25% ahead of last year, compared with the 15% increase that had been projected as the post World War II generation reached eligibility for early retirement, according to the SSA. The SSA and other analysts believe that due to immediate financial pressures many of the additional retirees were probably laid-off workers who claimed Social Security benefits early, despite the fact that these benefits would be reduced. 10 For insured workers contemplating early retirement, the choices in health insurance coverage after retirement may be limited. If they retire before they are eligible for Medicare at age 65, they can purchase an individual health insurance policy. But if they do so, they might encounter problems such as prohibitive costs for individual health insurance, especially if premiums are based on the retiree s age and health status. Early retirees may no longer have a funded prescription benefit and have to rely on discount or cash card discount programs. 11 Trends for 2009 will certainly be impacted by the state of the economy. PRESCRIPTION DRUG TRENDS: PART 2 Part 2 of the article will include therapeutic class detail by generation, including a comparison of 2007 and 2008 class ranking, and the PMPM gross and utilization trends for the top 10 therapeutic classes. Author Affiliations: From the Division of Analytics & Outcomes (AAT), CVS Caremark, Scottsdale, AZ; and the Division of Analytics & Outcomes (JAS, JS, SMF), Northbrook, IL. Address correspondence to: Anna A. Theodorou, RPh, MBA, Director, Industry Analytics, CVS Caremark, 9501 E Shea Blvd, Scottsdale, AZ anna.theodorou@caremark.com. REFERENCES 1. Daemmrich A, Bowden ME. A rising drug industry. The top pharmaceuticals that changed the world [special issue]. Chemical & Engineering News. June 20, 2005;83(25). coverstory/83/8325/index.html. Accessed June 3, Bellis M. 20th Century - the technology, science, and inventions. Accessed May 30, Cowen and Company, LLC. Epilepsy. In: Therapeutic Categories Outlook. New York, NY: Cowen & Co LLC; October 2007: McManus B. Pfizer s Lyrica is first drug approved for fibromyalgia. The Pink Sheet Daily. June 21, 2007;19(120, No. 008). 5. Off-label use study prompts disagreement on both problem and solution. The Pink Sheet. May 22, 2006;68(No. 21). 6. Moon MA. SSRIs, SNRIs linked to upper GI bleeding. Health News Daily. July 8, 2008;20(131). 7. American Diabetes Association. Economic costs of diabetes in the US in 2007 [published correction appears in Diabetes Care. 2008;31(6):1271]. Diabetes Care. 2008;31(3): Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the US population in and Diabetes Care. 2009;32(2): Tahmincioglu E. Under 30? Looking for a job? You re not alone. MSNBC.com. January 16, id/ /. Accessed May 22, Dorning M. Early retirement claims increase dramatically. The Los Angeles Times. May 24, nationworld/nation/la-na-retirement may24,0, story. Accessed June 3, Karoly LA, Rogowski J. Effects of Access to Post-Retirement Health Insurance on Retirement Behavior and Insurance Coverage. Research Highlights RAND Health RB Accessed June 3, VOL. 1, NO. 2 The American Journal of Pharmacy Benefits 115

The year 2009 has been one of economic uncertainty,

The year 2009 has been one of economic uncertainty, Recent Trends in Utilization of Antianxiety Medication Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; Julie Slezak, MS; and John A. Szychowski, BS The year 2009 has been one of economic

More information

Specialty drugs are a significant cost trend driver for

Specialty drugs are a significant cost trend driver for 2009 Drug Utilization and Cost Trends: Tumor Necrosis Factor Inhibitors Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; and John A. Szychowski, AAS, BS Specialty drugs are a significant

More information

Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at:

Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at: Hospital to Retail Spillover Analysis and Its Impact on Commercial Decision Making Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at: 1 Disclaimer The information provided and

More information

Cost-Motivated Treatment Changes in Commercial Claims:

Cost-Motivated Treatment Changes in Commercial Claims: Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical

More information

The proportion of Americans diagnosed with

The proportion of Americans diagnosed with Drug Utilization Patterns in Patients With Alzheimer s Disease Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; Marsha Moore, MD, MBA; Stacey Ruf, PhD; Tamra Wade; John A. Szychowski, AAS,

More information

Your Prescription Card. Your guide for savings.

Your Prescription Card. Your guide for savings. CVS Caremark 620 Epsilon Drive Pittsburgh, PA 15238 4750-_PM 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 Your Prescription Card. Your guide for savings. Dear Plan Member, Welcome to your new benefits. Attached

More information

High levels of cholesterol lead to an accretion

High levels of cholesterol lead to an accretion 2009 Drug Utilization and Cost Trends in Lipid-Lowering Agents Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; and John A. Szychowski, AAS, BS High levels of cholesterol lead to an accretion

More information

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action

More information

Covered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation Avalere.

Covered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation Avalere. Covered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation 2015 Avalere.com About the Researchers ABOUT THE CALIFORNIA HEALTHCARE FOUNDATION

More information

Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve.

Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve. Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve April 22, 2015 Qualis Health A leading national population health management organization

More information

MArch The 2014 Drug Trend Report Highlights

MArch The 2014 Drug Trend Report Highlights MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers

More information

taking at (Jan. 21, 2016) by Older 2016.pdf).

taking at (Jan. 21, 2016) by Older 2016.pdf). HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE

More information

The 2010 CVS Caremark Book of Business drug

The 2010 CVS Caremark Book of Business drug Drug Trends Gaining Insight Into the 2010 Drug Trend and Beyond Anna A. Theodorou, RPh, MBA; and John A. Szychowski, AAS, BS The 2010 CVS Caremark Book of Business drug trend was 2.4%, the lowest in 6

More information

United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America

United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America September 26, 2017 USND Report Background This report is the culmination of research to identify and better

More information

Prescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service

Prescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service Prescription Drugs Medicare & Medicaid Briefings National Health Policy Forum February 22, 2007 Jim Hahn Congressional Research Service Global and US. Prescription Drug Sales, 1998-2005 $700 $600 559 602

More information

$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2)

$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2) Benefit Summary Outpatient Prescription Drug Illinois 5/50/100/250 Plan 455 Your Co-payment and/or Co-insurance is determined by the tier to which the Prescription Drug List (PDL) Management Committee

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Neuropathic Pain (NP) in the US The US NP market was valued

More information

Your Kailos Test. Sample ID: CL-4194-DM. Jane Doe DOB: Hello Jane,

Your Kailos Test. Sample ID: CL-4194-DM. Jane Doe DOB: Hello Jane, 1 Jane Doe DOB: 1985-01-05 Sample ID: CL-4194-DM Hello Jane, Thank you for ordering your Kailos test for antidepressants. Kailos Genetics is committed to making gene-based healthcare available to YOU.

More information

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director Prescription Drugs North Carolina Policies Carol Steckel, MPH Medicaid Director March 19, 2013 Pharmacy Services Optional service provided each year to about 1.5 million beneficiaries by 2,200 pharmacy

More information

PREPARED BY THE CENTER FOR MEDICARE ADVOCACY, INC.

PREPARED BY THE CENTER FOR MEDICARE ADVOCACY, INC. MEDICARE DRUG CARDS PROVE INCONSISTENT AND PROVIDE FEW DISCOUNTS FOR MEDICARE BENEFICIARIES TRYING TO REDUCE THE COST OF THE TEN MOST POPULAR BRAND-NAME DRUGS USED BY SENIORS PREPARED BY THE CENTER FOR

More information

Joint Meeting. and the Peripheral and Central Nervous System Drugs Advisory Committee of the Center for Drug Evaluation and Research

Joint Meeting. and the Peripheral and Central Nervous System Drugs Advisory Committee of the Center for Drug Evaluation and Research Testimony to the Department of Health and Human Services Food and Drug Administration Joint Meeting of the Dental Products Panel of the Medical Devices Advisory Committee of the Center for Devices and

More information

In clinical studies, gabapentin efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day (1-3).

In clinical studies, gabapentin efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day (1-3). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.17 Subject: Gabapentin Page: 1 of 6 Last Review Date: June 22, 2017 Gabapentin Description Gabapentin

More information

Save Lives and Save Money

Save Lives and Save Money Tobacco Control Policies & Programs Save Lives and Save Money Matthew L. Myers President, Campaign for Tobacco Free Kids Alliance for Health Reform Luncheon Briefing July 13, 2012 1 We Know How to Reduce

More information

2017 Drug Trend Report Commercial Medicare Medicaid Exchanges

2017 Drug Trend Report Commercial Medicare Medicaid Exchanges 2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members

More information

Improving Mental Health Care: A Case Study

Improving Mental Health Care: A Case Study Improving Mental Health Care: A Case Study Why Improve Mental Health Care? Because the prevalence and costs of mental health problems are increasing in America despite the high prescribing of psychotropic

More information

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.

More information

Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018

Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018 Question: Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018 An examination of health improvements, utilization & cost of care for

More information

Your Prescription Card. Your guide for savings.

Your Prescription Card. Your guide for savings. Kent State University P.O. Box 5190 Kent, OH 44242-0001 13578-00001_PM JOHN Q SAMPLE 2215 SANDERS RD NBT 2215-5 NORTHBROOK, IL 60062 Your Prescription Card. Your guide for savings. 00001 Dear Plan Member,

More information

What you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh)

What you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh) SEE IF YOU CAN BREAK FREE WITH NORTHERA (droxidopa) What you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh) Use NORTHERA (droxidopa) is a prescription

More information

Medicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment

Medicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment American Hospital association December 2012 TrendWatch Are Medicare Patients Getting Sicker? Today, Medicare covers more than 48 million people, and that number is growing rapidly baby boomers are reaching

More information

Drug Use Criteria: Oral Ketorolac/Intranasal Ketorolac (Sprix )

Drug Use Criteria: Oral Ketorolac/Intranasal Ketorolac (Sprix ) Texas Vendor Program Use Criteria: Oral Ketorolac/Intranasal Ketorolac (Sprix ) Publication History 1. Developed February 1995. 2. Revised May 2016; December 2014; March 2013; May 2011; January 2009; October

More information

A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH:

A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: Amputee Coalition of America Mended Hearts National Federation of the Blind National Kidney Foundation

More information

Like others here today, we are very conflicted on the FDA s proposal on behind-thecounter medications, but thank you for raising the issue.

Like others here today, we are very conflicted on the FDA s proposal on behind-thecounter medications, but thank you for raising the issue. Statement of Consumers Union William Vaughan, Senior Policy Analyst before the US Food and Drug Administration Public Meeting on Behind the Counter Availability of Drugs November 14, 2007 Consumers Union

More information

TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE

TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE INTRODUCTION This Data Digest reports on changes in manufacturer prescription drug prices

More information

Substance Misuse in New Hampshire: An Update on Costs to the State s Economy and Initial Impacts of Public Policies to Reduce Them

Substance Misuse in New Hampshire: An Update on Costs to the State s Economy and Initial Impacts of Public Policies to Reduce Them Substance Misuse in New Hampshire: An Update on Costs to the State s Economy and Initial Impacts of Public Policies to Reduce Them May 2017 Prepared by: Sponsored by: Table of Contents EXECUTIVE SUMMARY...

More information

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations

More information

61 Recommendations for better use of medications

61 Recommendations for better use of medications Chapter 61 Recommendations for better use of medications As stated elsewhere in this book, we are fortunate to have a number of effective medications for treatment of many medical conditions. The drug

More information

Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015

Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015 Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead

More information

This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both

This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both direct and indirect and the projected burden of diabetes,

More information

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this

More information

june drug trend report featuring the pharmacy benefit guide

june drug trend report featuring the pharmacy benefit guide june 2005 2004 drug trend report featuring the pharmacy benefit guide Preface Dear Reader, This ninth publication of Express Scripts annual Drug Trend Report coincides with a significant milestone for

More information

Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices

Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices Authors: Jean Fuglesten Biniek William Johnson January 2019 Insulin Prices Were the Primary Driver of Rapid

More information

RE: Proposed Decision Memo for Screening for Hepatitis C Virus (HCV) in Adults (CAG-00436N)

RE: Proposed Decision Memo for Screening for Hepatitis C Virus (HCV) in Adults (CAG-00436N) April 2, 2014 Tamara Syrek Jensen, JD Acting Director Coverage and Analysis Group Center for Clinical Standards and Quality Centers for Medicare and Medicaid Services U.S. Department of Health and Human

More information

Medicaid in South Carolina. South Carolina Medicaid in /19/2018. > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1.

Medicaid in South Carolina. South Carolina Medicaid in /19/2018. > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1. Medicaid in South Carolina > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1.04 million South Carolina Medicaid in 2018 Bryan Amick SC Chapter, American Academy of Pediatrics 2018 CATCH

More information

A nation in pain: Focus on Medicaid

A nation in pain: Focus on Medicaid DATA INSIGHTS A nation in pain: Focus on Medicaid Opioid pain medications have become one of the most controversial classes of prescription therapy. While they provide great benefits in controlling both

More information

Berkshire Allergy & Asthma Center 2210 Ridgewood Road, Suite 100 Wyomissing, PA (610)

Berkshire Allergy & Asthma Center 2210 Ridgewood Road, Suite 100 Wyomissing, PA (610) Berkshire Allergy & Asthma Center 2210 Ridgewood Road, Suite 100 Wyomissing, PA 19610 (610) 372-0502 It is with pleasure that we welcome you as a new patient to Berkshire Allergy & Asthma Center, a division

More information

See reverse side for important facts about how to save on your prescriptions.

See reverse side for important facts about how to save on your prescriptions. The University of Akron Benefits Administration Akron, OH 44325-4704 > 001 P50708 _PM 6088 GROUP JOHN Q SAMPLE 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 Use your card to save on prescriptions. Because saving

More information

Realized Savings from Generic Drugs in Upstate New York

Realized Savings from Generic Drugs in Upstate New York T H E F A C T S A B O U T Realized Savings from Generic Drugs in Upstate New York More Than $130 Million Saved in 2006 Compared With 2005 Finger Lakes Region Estimated generic savings: $29 million Generic

More information

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee

More information

WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? INDICATIONS IMPORTANT RISK INFORMATION

WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? INDICATIONS IMPORTANT RISK INFORMATION WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? Learn how DELZICOL can help you manage your ulcerative colitis INDICATIONS DELZICOL (mesalamine) delayed-release capsules is a prescription medication

More information

The State of Obesity 2017 Better Policies for a Healthier America

The State of Obesity 2017 Better Policies for a Healthier America The State of Obesity 2017 Better Policies for a Healthier America Southern Obesity Summit Atlanta, GA October 2, 2017 Richard Hamburg Executive Vice President and COO Trust for America s Health Overview

More information

Your Prescription Card. Your guide for savings.

Your Prescription Card. Your guide for savings. 3 Paragon Drive Montvale, NJ 07645 >00001 00001 001 P50708 _PM 7873 GROUP JOHN Q SAMPLE 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 APDNCLDJDKDIFPAKHPANEMFK AJCLLKEBEKNJJBNMPKGOKIKK AMBPIBPEAKHEIOBKFGFBOMMK

More information

Alzheimer s disease affects patients and their caregivers. experience employment complications,

Alzheimer s disease affects patients and their caregivers. experience employment complications, Alzheimer s Disease and Dementia A growing challenge The majority of the elderly population with Alzheimer s disease and related dementia are in fair to poor physical health, and experience limitations

More information

Prescription drug expenditures are the most rapidly growing component

Prescription drug expenditures are the most rapidly growing component Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid Kenneth S. Fink, MD, MGA, MPH 1 Patricia J. Byrns, MD 2 1 Department of Family Medicine, University of North Carolina

More information

Market Potential for MDX Alcobra Investor Breakfast July 15, 2014

Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases,

More information

Drug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources

Drug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources Drug Utilization Review & Cost Reduction Strategies Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources Goals and Objectives Define Drug Utilization Reviews Interpret various performance

More information

If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA

If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA IMPORTANT SAFETY INFORMATION WARNING: HYPONATREMIA See full prescribing information for complete boxed warning. NOCTIVA

More information

Opioid Addiction Statistics

Opioid Addiction Statistics May 2017 Opioid Addiction Statistics Definitions Heroin Epidemic - As pill mills close, prescribing is becoming tighter, demand among younger users rise, and dealer s profits rise, addicts are turning

More information

RECEIVING YOUR PERMANENT

RECEIVING YOUR PERMANENT 00001 JOHN Q SAMPLE 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 3118-00001_PM City of Savannah 132 E. Broughton Street Savannah, GA 31401 THIS IS A ONE-TIME CARD TO BE USED UNTIL YOUR PERMANENT CARD ARRIVES

More information

Executive Summary. Overall conclusions of this report include:

Executive Summary. Overall conclusions of this report include: Executive Summary On November 23, 1998, 46 states settled their lawsuits against the nation s major tobacco companies to recover tobacco-related health care costs, joining four states Mississippi, Texas,

More information

Russia Editors: LEO Innovation Lab and The Happiness R s esearch Institute Copenhagen, Denmark, October 2018

Russia Editors: LEO Innovation Lab and The Happiness R s esearch Institute Copenhagen, Denmark, October 2018 Russia Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any

More information

Medicaid Perspective

Medicaid Perspective Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:

More information

Value Based Pay for Performance Results & Highlights Measurement Year September 2017

Value Based Pay for Performance Results & Highlights Measurement Year September 2017 Value Based Pay for Performance Results & Highlights Measurement Year 2016 September 2017 IHA s Value Based Pay for Performance (VBP4P) ~200 Medical Groups & IPAs 9 Health Plans Common Measurement Public

More information

COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO

COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO Our Ask That the Ontario government: Renew their commitment to achieving the lowest smoking rate in Canada Align the Smoke Free Ontario Strategy with the proposed

More information

FlexRx 6-Tier. SM Pharmacy Benefit Guide

FlexRx 6-Tier. SM Pharmacy Benefit Guide FlexRx 6-Tier SM Pharmacy Benefit Guide Welcome to FlexRx The AllWays Health Partners FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many

More information

Issues for Part D Compliance

Issues for Part D Compliance HCCA- MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE Issues for Part D Compliance Craig Miner, RPh, JD Division of Drug Plan Policy Babette S. Edgar, Pharm.D., MBA Division of Finance and Operations

More information

Merkin Brain and Health Policy Innovation Program 2013

Merkin Brain and Health Policy Innovation Program 2013 Merkin Brain and Health Policy Innovation Program 2013 Table of Contents Meet 2013 Fellow Daniella Meeker Research Spotlight on Alzheimer s Disease Meet 2013 Fellow Daniella Meeker 1 Research Spotlights:

More information

Spain Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018

Spain Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018 Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of

More information

THE IOWA CONSORTIUM FOR SUBSTANCE ABUSE RESEARCH AND EVALUATION. Special Report: Opioid Admissions in Iowa August 2016

THE IOWA CONSORTIUM FOR SUBSTANCE ABUSE RESEARCH AND EVALUATION. Special Report: Opioid Admissions in Iowa August 2016 Special Report: State of Iowa Opioid Treatment Admissions 21-215 THE IOWA CONSORTIUM FOR SUBSTANCE ABUSE RESEARCH AND EVALUATION Special Report: Opioid Admissions in Iowa 21-215 August 216 With Funds Provided

More information

The Impact of Tiered Co-Pays A Survey of Patients and Pharmacists

The Impact of Tiered Co-Pays A Survey of Patients and Pharmacists The Impact of Tiered Co-Pays A Survey of Patients and Pharmacists Research Report Conducted by Harris Interactive September, 2003 This study was completed on behalf of and with support from the National

More information

Where We Are: State of Tobacco Control and Prevention

Where We Are: State of Tobacco Control and Prevention Where We Are: State of Tobacco Control and Prevention Corinne Husten, MD, MPH Acting Director CDC Office on Smoking and Health Nova Scotia, Canada October 2006 Tobacco Impact Background Tobacco is leading

More information

Lyrica. Lyrica (pregabalin) Description

Lyrica. Lyrica (pregabalin) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Lyrica Page: 1 of 6 Last Review Date: June 22, 2017 Lyrica Description Lyrica (pregabalin)

More information

Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain

Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted

More information

The motivation to volunteer varies for each

The motivation to volunteer varies for each Give M O r e T o M o t i v a t i o n s a n d B a r r i e r s Motivating a Generation The motivation to volunteer varies for each individual, with some volunteers hoping to make a difference, some looking

More information

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences

More information

Coventry Health Care of Georgia, Inc.

Coventry Health Care of Georgia, Inc. Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

Understanding Your Patient Care Opportunity Report (PCOR)

Understanding Your Patient Care Opportunity Report (PCOR) Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient

More information

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior

More information

AVEED TESTOSTERONE INJECTION. Not an actual patient.

AVEED TESTOSTERONE INJECTION. Not an actual patient. Ask your healthcare provider about LONG-ACTING AVEED AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR AFTER THE FIRST MONTH OF THERAPY Not an actual patient. AVEED is a prescription medicine that contains testosterone,

More information

Denmark Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018

Denmark Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018 Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of

More information

http://results.harrispollonline.com/surveyresults/default.asp?file=page1.html In general, how would you describe your own health? 16% 34% 29% 13% 7% Excellent Very good Good Fair Poor http://results.harrispollonline.com/surveyresults/default.asp?file=page2.html

More information

The New Medtech Economic Reality MassMEDIC Annual Meeting

The New Medtech Economic Reality MassMEDIC Annual Meeting The New Medtech Economic Reality MassMEDIC Annual Meeting Susan Posner Vice President sposner@healthadvances.com May 1, 2012 The New Medtech Reality The economic downturn coupled with the focus on health

More information

The 465 medicines in development include: 142 for diabetes, which affects 10.9 million Americans age 65 and older;

The 465 medicines in development include: 142 for diabetes, which affects 10.9 million Americans age 65 and older; Medicines in Development Older Americans The Medicare Population and Leading Chronic Diseases presented by america s biopharmaceutical research companies Overview 2013 REPORT Biopharmaceutical Research

More information

Blue Cross of Idaho Addresses State s Opioid Issue

Blue Cross of Idaho Addresses State s Opioid Issue Blue Cross of Idaho Addresses State s Opioid Issue BY THE NUMBERS - Opioid Management page 3 THE PROBLEM - How Preventing Pain Hurt Us page 4 THE SOLUTIONS - Idaho State Board Of Pharmacy Prescription

More information

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: CARD/MAIL/PRE-APPROVAL/PREFERRED The Prescription Drug Coverage under this Rider [replaces] [supplements] the Prescription

More information

National health-care expenditures are projected to rise to $5.2 trillion by 2023

National health-care expenditures are projected to rise to $5.2 trillion by 2023 National health-care expenditures are projected to rise to $5.2 trillion by 2023 US$ trillions 6 5 4 3 2.3 2.5 2.7 2.9 3.2 3.6 4.0 4.6 5.2 2 1 0 2007 2011 2015* 2019* 2023* * Projected. Source: Centers

More information

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013

More information

MARCH Funding the Miracles: Best Practices for Managing Spinraza and Other Orphan Drugs Archimedes, LLC. All Rights Reserved

MARCH Funding the Miracles: Best Practices for Managing Spinraza and Other Orphan Drugs Archimedes, LLC. All Rights Reserved MARCH 27 Funding the Miracles: Best Practices for Managing Spinraza and Other Orphan Drugs 27 Archimedes, LLC. All Rights Reserved Spinraza Overview In a development described by patient advocates as an

More information

Medication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes

Medication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry

More information

Elements for a Public Summary Overview of disease epidemiology

Elements for a Public Summary Overview of disease epidemiology VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other

More information

New Jersey s Comprehensive Tobacco Control Program: Importance of Sustained Funding

New Jersey s Comprehensive Tobacco Control Program: Importance of Sustained Funding New Jersey s Comprehensive Tobacco Control Program: Importance of Sustained Funding History of Tobacco Control Funding Tobacco use is the leading preventable cause of death in the U.S., killing more than

More information

REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Lidoderm/Versatis in the 7MM neuropathic

More information